Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 200 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $33.750 million which beat the analyst consensus estimate of $11.468 million by 194.29 percent. This is a 233.73 percent increase over sales of $10.113 million the same period last year.